Holen Sie sich die Stockscreener-App
116.79
1.03%
-1.21
Handel nachbörslich:
117.50
0.71
+0.61%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$118.00
Offen:
$118.53
24-Stunden-Volumen:
1.13M
Relative Volume:
1.25
Marktkapitalisierung:
$11.66B
Einnahmen:
$1.64B
Nettoeinkommen (Verlust:
$121.85M
KGV:
75.84
EPS:
1.54
Netto-Cashflow:
$-480.40M
1W Leistung:
-1.72%
1M Leistung:
-1.83%
6M Leistung:
-19.79%
1J Leistung:
+0.99%
1-Tages-Spanne:
$116.21
$119.51
1-Wochen-Bereich:
$114.42
$123.02
52-Wochen-Spanne:
$102.16
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
116.79 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Smith Salley Wealth Management Buys Shares of 7,308 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Assenagon Asset Management S.A. Sells 217,594 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
What is HC Wainwright's Forecast for SRPT FY2024 Earnings? - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright - MarketBeat
HC Wainwright Issues Positive Estimate for SRPT Earnings - MarketBeat
Sarepta preliminary Q4 revenue beats, but full year just misses - MSN
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics - Benzinga
J&J files a potential blockbuster; Lykos shakes up its board - BioPharma Dive
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Harbor Capital Advisors Inc. Acquires 427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint
Sarepta Bullish After Another Big Beat For Elevidys - News & Insights
Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat - BioSpace
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Sarepta exceeds revenue forecasts, maintains 2025 guidance - Investing.com India
Sarepta Therapeutics Tops 2024 Net Product Revenue Guidance - MarketWatch
Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue - StreetInsider.com
Sarepta Therapeutics Smashes Revenue Targets as ELEVIDYS Sales Surge 112% in Q4 2024 - StockTitan
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Nordea Investment Management AB - MarketBeat
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - MarketBeat
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com Canada
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Nippon Shinyaku Hit With Royalty Tab After $115 Million Verdict - Bloomberg Law
SRPT February 28th Options Begin Trading - Nasdaq
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? - MSN
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference - Benzinga
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $178.71 - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
LABU, NTRA, INCY, SRPT: Large Inflows Detected at ETF - Nasdaq
Sarepta Therapeutics Grants 10,660 RSUs to New Employees in Strategic Talent Acquisition Move - StockTitan
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Duchenne Muscular Dystrophy Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeuti - Barchart
Exploring High Growth Tech Stocks in the US December 2024 - Simply Wall St
Page 4 | SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView
SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView
Principal Financial Group Inc. Sells 95,974 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):